Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?
TheFly reported on June 22 that KeyBanc adjusted its price target for RMD to $266 from $290 while maintaining an Overweight rating on the shares.
Resmed Inc (RMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 450,250 | $101,072,120 | +65% | 0.05% |
| 2. | Ilex Capital Partners Jonas Diedrich And David Sutton | 413,855 | $92,902,170 | +69% | 2.29% |
| 3. | 400,000 | $89,792,000 | 7.22% | ||
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 381,296 | $85,593,329 | 0.09% | |
| 5. | AQR Capital Management Cliff Asness | 349,840 | $77,797,404 | +37% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.13 | 2,487 | $171,926.31 | 19,216 | 2016-08-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $218.55 | 4,991 | $1,090,770.57 | 466,223 | 2026-07-07 | Filing | |
| $193.96 | 4,991 | $968,064.34 | 466,256 | 2026-06-08 | Filing | |
| $207.82 | 4,991 | $1,037,232.61 | 466,223 | 2026-05-07 | Filing | |
| $225.50 | 4,991 | $1,125,486.47 | 466,223 | 2026-04-07 | Filing | |
| $224.31 | 1,000 | $224,310.00 | 83,495 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,274,897 | $248,451,928 | 0.21% | |
| 2. | 150,600 | $29,348,928 | 0.64% | |
| 3. | 94,086 | $18,335,407 | 0.29% | |
| 4. | 83,852 | $16,341,078 | 0.02% | |
| 5. | 77,707 | $15,143,540 | 0.41% |
News See All
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The U.S. healthcare sector has significantly lagged the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
Is ResMed Inc. (RMD) A Good Stock To Buy Now?
Is RMD a good stock to buy? We came across a bullish thesis on ResMed Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on RMD.
10 Most Undervalued Large Cap Stocks to Buy According to Analysts
On May 26, Eddie Ghabour, CEO of Key Advisors Wealth Management, joined BNN Bloomberg to discuss the market outlook amid volatility. The market is experiencing record highs despite ongoing challenges.
ResMed Inc. (NYSE:RMD) Q3 2026 Earnings Call Transcript
Operator: Welcome to the Q3 Fiscal Year 2026 ResMed Inc. Earnings Conference Call. My name is Daryl, and I will be your operator for today's call.
8 Best Long-Term ASX Stocks to Buy Right Now
Based on Reuters’ report dated April 14, 2026, consumer sentiment in Australia has softened significantly, as highlighted by the Westpac-Melbourne Institute Index’s 12.5% drop to 80.1 in April, its...
ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings
ResMed Inc. (NYSE:RMD) is one of the best medical technology stocks to invest in. On January 30, KeyBanc Capital Markets lifted its price target on ResMed Inc.
10 Best Medical Technology Stocks to Invest In
Medical technology, or MedTech, companies ensure that the broader healthcare industry has the tools needed to diagnose, treat, monitor, or prevent medical conditions.
ResMed Inc. (RMD): A Bull Case Theory
We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls’ thesis on RMD.
ResMed Inc. (NYSE:RMD) Q2 2026 Earnings Call Transcript
Operator: Greetings, and welcome to the ResMed Second Quarter Fiscal Year 2026 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded.